Jiangsu Yasheng Pharmaceutical Development

Ascentage Pharma is a global clinical-stage biotechnology company dedicated to developing novel therapies for cancers, hepatitis B virus (HBV), and age-related diseases. The company focuses on disrupting protein-protein interactions to restore apoptosis, or programmed cell death, in cancer cells. Its lead product, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor approved in China for the treatment of drug-resistant chronic myeloid leukemia. Ascentage maintains a robust pipeline of small molecule inhibitors targeting key pathways such as BCL-2, IAP, and MDM2-p53. Headquartered in Suzhou, China, the company also maintains significant R&D operations in Rockville, Maryland, and is publicly traded on the Hong Kong Stock Exchange.